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Abstract
Background: While pain is a common symptom in JIA patients, it remains unclear why some JIA patients develop
ongoing or persistent pain. Complex clinical and social settings confound analysis of individual factors that may
contribute to this pain. To address this, we first undertook a retrospective analysis of pain reports in a JIA patient
cohort with the aim of identifying potential factors contributing to persistent pain. We then carried out an
experimental laboratory study, using joint inflammatory pain behaviour in rodents, to validate the role of these
factors in the onset of persistent pain under controlled conditions.
Methods: Patients: Retrospective analysis of anonymised pain visual analogue scale (VAS) scores and accompanying
clinical scores from 97 JIA patients aged 13–19 (mean: 16.40 ± 1.21) collected over 50 weeks. Rats: Experimental study
of pain behaviour following intra-articular microinjection of complete Freund’s adjuvant (CFA) in adolescents (n = 25)
and young adults (n = 43). Some animals (n = 21) had been previously exposed to joint inflammation in infancy or
adolescence.
Results: Patients: Cluster analysis of patient pain VAS scores revealed three trajectories over 50 weeks: consistently low
pain (n = 45), variable pain (n = 30) and persistently high pain (n = 22). Number of actively inflamed joints did not differ
in the three groups. High pain at a single visit correlated with greater physician global assessment of disease activity,
while a high pain trajectory over 50 weeks was associated with more limited joints but fewer actively inflamed joints.
Rats: Rodents administered ankle joint CFA also exhibit low, medium and high joint pain sensitivities, independent of
joint inflammation. Prolonged inflammatory pain behaviour was associated with high background pain sensitivity,
following joint inflammation at an earlier stage in life.
Conclusions: Both JIA patients and rodents differ in their individual pain sensitivity independent of the concurrent
joint inflammation. Using experimental animal models allows us to isolate physiological factors underlying these
differences, independently of social or clinical factors. The results suggest that a history of prior arthritic activity/joint
inflammation may contribute to high pain sensitivity in adolescents with JIA.
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Background
Juvenile idiopathic arthritis (JIA) is a heterogenous group of
inflammatory arthritides affecting 1 in 1000 children in the
UK [1]. At least 70% of children with JIA report regular inci-
dences of pain [2–4] and patients can continue to experi-
ence pain up to 30 years after JIA onset [5]. Chronic pain
correlates with disability [2] and quality of life [6] in these
patients; yet the prevalence of pain has barely improved des-
pite increasing awareness and improving therapeutics [6, 7].
Recent studies show that only a subset of children with
JIA (10–20%) develop persistent pain over 5 years from
disease onset [8–10]. These findings suggest that pain sen-
sitivity may vary in JIA patients and that certain biological
and psychosocial factors may contribute to this sensitivity
and the development of persistent pain. Age, [8–11] sex,
[8, 12, 13] JIA subtype and arthritic activity, [10–12], dis-
ease duration, [9] symptoms of depression or anxiety, [3,
13, 14] stressful events [4], and dysfunctional health beliefs
[15, 16] have all been implicated as possible contributing
factors. However, evidence for the role of these factors in
the development of pain is mixed. For example, the role of
arthritic activity is disputed with some studies finding that
the presence of active arthritis had no effect on pain sensi-
tivity [13, 17] and others finding that increased numbers
of inflamed joints are linked to a more persistent pain
state in the following days [3] to years [8, 10].
Understanding the factors determining pain trajectory is
crucial to furthering our understanding of JIA pain, but
assessing the relative contribution of individual factors is
extremely difficult in patient cohorts. Animals models
provide an alternative approach – allowing contributing
factors to be assessed in a controlled setting [18]. Age ap-
propriate models of joint inflammation or arthritis allow
individual factors to be adjusted and their influence on in-
flammatory pain in juveniles quantified, while also con-
trolling for confounding variables such as disease activity,
environment, genetic risk factors and maternal influences.
In the first part of this study we have undertaken a
retrospective analysis of pain reports in a JIA patient co-
hort with the aim of identifying biological factors that
explain reports of persistent pain. In the second part we
have used an experimental rodent model of joint inflam-
matory pain, to validate the role of these factors in de-
termining pain sensitivity in these models.
Methods
Part 1: patient cohort
Study design
This part of the study is a retrospective analysis of data
collected from patients with JIA and their physicians at
clinic visits to University College London Hospital.
The data follows an observational study design exam-
ining factors influencing pain in a cross-section of
adolescents with JIA.
Study population and data collection
Study participants attended routine clinical appointments
at University College London Hospital between 2014 and
2018. At each appointment, patients completed a ques-
tionnaire which included the 10 cm pain Visual Analogue
Scale (VAS), the Childhood Health Assessment Question-
naire (CHAQ) and a 10 cm patient general evaluation
VAS (PGE). Concurrently, physicians completed a 10 cm
physician global assessment VAS (PGA) and recorded the
number of active (inflamed), swollen and limited joints.
Patient characteristics (age, gender, age of JIA onset, JIA
subtype, medications) were noted for each appointment.
All data was anonymised prior to patient selection and
statistical analysis.
Disease activity markers erythrocyte sedimentation
rate and c-reactive protein levels were only available for
43% of clinic visits because blood sampling is only rou-
tine practice in patients receiving disease-modifying anti-
rheumatic drugs (DMARDs) or biologics and because
the data was only available if blood sampling coincided
with a clinic visit. As such these factors could not be in-
cluded in the analysis without losing statistical power.
Information on disease markers for each pain trajectory
is available in Additional file 1: Table S1.
Physician reported outcomes are drawn from evaluations
made during clinical appointments. Several rheumatolo-
gists contributed to the data with an agreed consensus
between physicians. Intra-investigator variation was not
assessed due to the retrospective nature of this study.
Patient selection
In total, 282 patients with JIA attended the clinic for at
least 1 year. Sixteen were excluded due to a change to a
non-JIA diagnosis. The remaining patients made 1714
clinic visits overall with varying intervals between ap-
pointments. Completion of the patient questionnaire
varied (67.3% completed). Physician-reported measures
(PGA and joint counts) were reported at 80.4% of visits.
Patient characteristics are shown in Table 1.
Only patients with 3 pain VAS scores obtained at 25 ±
7 week intervals were included in the analysis. Data col-
lection was opportunistic, leading to the following exclu-
sions: 60 patients with an insufficient number of pain
VAS scores, 104 patients with incorrect time intervals
between visits, and 5 patients due to missing baseline
variables. The exclusion criteria are shown in Fig. 1 and
the characteristics of excluded patients are shown in
Additional file 1: Table S2.
In total, 97 patients were included in this analysis (Fig.
1), aged 13.77–19.44 years old (mean: 16.40 ± 1.21) with
the age of JIA diagnosis ranging from 0.97–17.00 years
old (mean: 9.62 ± 4.86). Disease duration at study onset
ranged from 0.22–17.45 years (mean: 6.78 ± 5.17). 56.7%
of patients were female. Patients most commonly had
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JIA with a polyarticular course (55.7%). This subset was
made up of patients with either extended oligoarticular
JIA (37.04%) or polyarticular JIA (62.96%).
Statistical analysis
Analyses were performed using SPSS, version 25. Patient
pain trajectories were identified using hierarchical cluster
analysis. Distinctions between trajectories were identified
using repeated measures two-way ANOVA with Bonfer-
roni post-hoc analysis. Characteristics of patients with each
trajectory type were compared using either one-way
ANOVA or Chi-Square test, depending on the type of data.
The influence of current arthritic activity on pain was
determined using linear regression assessing the correl-
ation of physician-reported measures with pain at a sin-
gle clinic visit. PGA and the number of active joints for
each trajectory type were also compared using one-way
ANOVA with Bonferroni post-hoc analysis.
Factors associated with each trajectory type in patients
were identified using multinomial logistic regression.
Physician-reported measures collected at study onset
and patient characteristics were included in this analysis.
In addition, the association of active, swollen or limited
joints (or a combination of the three) with trajectory
type was examined using Fisher’s Exact test.
Part 2: rodent model of monoarthritis
Study design
This part of the study examined factors, highlighted in
the analysis of patient data, in an experimental animal
model of monoarthritic pain. This allowed us to assess
their contribution to inflammatory pain sensitivity in the
absence of confounding factors.
Animal experiments were performed under a project
license from the UK Home Office. Male and female
Sprague-Dawley rats were bred and maintained in-house
at UCL under standard conditions (21-23oc, 12h light-
dark cycle) with unlimited food and water. Handling and
maternal separation of pups were kept to a minimum
and animals were exposed to the same standard caging,
handling and diet throughout.
Randomisation using a random number generator was
utilised wherever possible, including group allocation
and animal order while undergoing procedures. Blinding
Table 1 Patient characteristics at study onset
All patients Trajectory: Statistical analysis
Low pain Variable pain High pain F value/Chi-Square P value
No. of patients 97 45 (46.4%) 30 (30.9%) 22 (22.7%)
Age at JIA onset 9.62 (4.86) 9.51 (4.71) 9.96 (4.88) 9.40 (5.31) 0.11 0.90
Age at study onset 16.40 (1.21) 16.19 (1.18) 16.46 (1.16) 16.76 (1.31) 1.67 0.19
Years since JIA onset 6.78 (5.17) 6.68 (4.97) 6.49 (5.33) 7.36 (5.55) 0.19 0.83
Sex: 8.05 0.018
Female 55 (56.7%) 24 (53.3%) 13 (43.3%) 18 (81.8%)
Male 42 (43.3%) 21 (46.7%) 17 (56.7%) 4 (18.2%)
Weeks between:
Visit 1 and 2 24.12 (4.11) 24.24 (4.16) 24.30 (4.50) 23.64 (3.55) 0.20 0.82
Visit 1 and 3 49.11 (5.74) 49.27 (4.92) 48.63 (6.91) 49.45 (5.77) 0.16 0.86
JIA subtype: 11.77 0.067
Polyarticular course 54 (55.7%) 21 (46.7%) 16 (53.3%) 17 (77.3%)
Oligoarticular 6 (6.2%) 4 (8.9%) 1 (3.3%) 1 (4.5%)
Enthesitis Related 32 (33.0%) 15 (33.3%) 13 (43.3%) 4 (18.2%)
Systemic 5 (5.2%) 5 (11.1%) 0 (0.0%) 0 (0.0%)
JIA activity markers:
PGA (cm) 2.40 (2.52) 1.40 (2.11) 3.11 (2.73) 3.47 (2.31) 7.64 0.001
No. of active joints 0 (0–2) 0 (0–1) 1 (0–1) 0 (0–2) 2.06 0.13
Medications:
No. taking DMARDs 67 (69.1%) 27 (60.0%) 22 (73.3%) 18 (81.8%) 3.66 0.16
No. taking Biologics 40 (41.2%) 18 (40.0%) 12 (40.0%) 10 (45.5%) 0.21 0.90
No. taking Steroids 16 (16.5%) 4 (8.9%) 7 (23.3%) 5 (22.7%) 3.53 0.17
Data is presented as mean (standard deviation) for continuous data, number (% of patients with trajectory type) for categorical data or median (interquartile
range) for discrete data (e.g. joint count). Comparisons between trajectories which reach significance (p < 0.05) are indicated in bold. PGA = Physician global
assessment VAS. DMARDs = Disease-modifying antirheumatic drugs
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of group assignment was not possible due to the clear
differentiation in joint inflammation between experi-
mental and control animals. Full details of animal num-
bers are provided in Additional file 1: Table S3 and
Table S4.
Reporting on this study is based on the ARRIVE
Guidelines for Reporting Animal Research [19].
Monoarthritis induction
Monoarthritis was induced by a microinjection of complete
Freund’s adjuvant (CFA; Sigma-Aldrich, UK) into the
intraarticular space of the left ankle joint. Animals were
anaesthetised with isoflurane and a 30-gauge needle at-
tached to a 100 μl Hamilton syringe was inserted into the
ankle joint from the posterior lateral aspect. The minimum
volume of CFA required to produce acute arthritic inflam-
mation was administered, namely 2, 10, or 20 μl CFA for
animals aged postnatal day (P)8, P21 and P40 respectively
(human development equivalent: neonate, adolescent and
young adult respectively). Control animals were adminis-
tered sterile saline using the same procedure. In some
animals, intraarticular injections of CFA were administered
at two ages: either P8 or P21 and again at P40 (n = 12/sex).
Control animals received CFA for the first time at P40
(n = 12/sex) or saline (n = 12/sex). Three animals receiving
CFA twice were removed from the study due to excessive
joint inflammation and pain behaviour. Two animals were
excluded due to no pain behaviour post-CFA.
Behavioural testing
In all animals, mechanical withdrawal threshold, weight
bearing, and joint diameter of the ipsilateral hindlimb were
measured prior to CFA/saline injection (baseline) and regu-
larly (every 1–4 days) up to 24 days post-injection. Cali-
brated von Frey hairs were applied to the paw and the
mechanical withdrawal threshold was determined using the
up-down method as described elsewhere [20]. Thresholds
were transformed into a percentage change from baseline.
Hindlimb weight bearing was measured using an inca-
pacitance meter (Churchill Electronic Services) which
measures the weight supported by each hindlimb of a
stationary animal. Three readings collected over 1 min
were averaged and the weight borne by the ipsilateral
limb was expressed as a percentage of the weight borne
across both hindlimbs.
Ankle joint diameter was assessed as an indicator of the
extent of joint inflammation. This was measured using
callipers while the animal was standing. The joint was
measured across the widest point–the malleoli produced
by the fibula and tibia. Joint diameters were transformed
into a percentage change from baseline.
Fig. 1 Exclusion criteria used for the selection of JIA patients for the analysis of pain trajectories over 50 weeks and the resultant number of
patients included in this analysis
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Statistical analysis
Analyses were performed using SPSS, version 25. Sensitiv-
ities to inflammatory pain were identified using hierarch-
ical cluster analysis. Distinctions between different
sensitivities were identified using repeated measures two-
way ANOVA with Bonferroni post-hoc analysis. The
distribution of male and females across pain sensitivities
was examined using a Chi-Square test. The influence of
current joint inflammation on pain sensitivity was deter-
mined using a linear regression assessing the correlation of
joint diameter with % reduction in mechanical threshold 3
days after the induction of monoarthritis as well as a com-
parison of joint diameter across 21 days in animals with
different pain sensitivities using repeated measures two-
way ANOVA with Bonferroni post-hoc analysis.
To assess the effect of prior monoarthritis on pain sen-
sitivity, animal groups were compared using two-way
ANOVAs with Bonferroni post-hoc analysis. Compari-
son of weight bearing deficits present prior to the sec-
ond bout of monoarthritis (at baseline) were made using
one-way ANOVA with Bonferroni post-hoc analysis.
Results
Part 1: pain in adolescent JIA patients
Pain in JIA patients follows one of three trajectories over
50 weeks
Pain visual analogue scores (VAS) reported by patients var-
ied considerably at each clinic visit (range: 0.0–10.0 cm for
each visit; mean: 3.3 ± 2.9 cm, 3.4 ± 2.9 cm and 3.2 ± 3.2 cm
for each consecutive visit). Despite this variability, pain
VAS over the 3 clinic visits could be separated into 8
discrete clusters which were aggregated into 3 larger func-
tionally distinct pain trajectories based on proximity
between clusters (Fig. 2a): patients with consistently low
levels of pain (typically < 3.0 cm; 46.4% of patients, Fig. 2d),
patients with persistently high pain (typically ≥5.0 cm;
22.7%, Fig. 2b), and patients with varying pain levels (30.9%
of patients, Fig. 2c) across the 3 clinic visits. This final
group maintained average pain VAS of 5.1 ± 3.1 cm, 4.2 ±
2.9 cm and 4.1 ± 2.7 cm for each visit but consisted of pa-
tients with both large increases and decreases in pain be-
tween visits (as shown by the separate clusters in Fig. 2c).
Pain VAS significantly differed between the three tra-
jectory groups across clinic visits (F2,94 = 193.21, p <
0.001). Disability (CHAQ) and quality of life (PGE)
followed similar trajectories (Additional file 1: Figure
S1), differing significantly between groups (CHAQ:
F2,74 = 50.31, p < 0.001; PGE: F2,90 = 71.17, p < 0.001).
Patients in the three pain trajectories did not differ in
patient characteristics except for sex: females were more
prevalent in the high pain trajectory (Chi-square = 8.05,
p = 0.018) compared to either the low or variable trajec-
tories (Table 1).
Arthritic activity does not account for the differing pain
sensitivities in patients
In the patient cohort, pain at any individual clinic visit was
significantly associated with physician global assessment
(PGA) (odds ratio [OR](95% confidence interval [95%CI]) =
1.90(1.61–2.23), β= 0.51, p < 0.001; Fig. 2e) but not with the
number of active joints (OR(95%CI) = 0.98(0.83–1.16), β =
− 0.02, p= 0.81; Fig. 2f), or swollen (OR(95%CI) = 1.05(0.88–
1.24), β= 0.04, p= 0.61) or limited joints at that visit
(OR(95%CI) = 1.02(0.96–1.09), β= 0.04, p= 0.46). This
model examining variables influencing concurrent pain, ex-
plained a significant amount of the variance seen in pain
VAS scores (F = 24.90, p < 0.001) but not all (R2 = 0.28).
A high pain trajectory in patients is associated with limited
joints at study onset
Since pain is not associated with measures of current arth-
ritic activity, we investigated the association of factors at
study onset with pain trajectory. Average scores for PGA
was significantly higher (F2,94 = 7.64, p = 0.001) in patients
with variable (p < 0.05) or high (p < 0.01) pain compared
to those with low pain (Table 1), whereas the number of
active joints did not significantly differ between trajector-
ies (F2,94 = 2.06, p = 0.13), a pattern similar to that seen
when correlating pain and concurrent arthritis activity.
However, regression analysis assessing the influence of
disease activity markers alongside patients characteristics
showed that patients with a high pain trajectory were less
likely to have active joints at the onset of this study,
(OR(95%CI) = 0.62(0.40–0.97), p = 0.035) but they were
more likely to have swollen joints (OR(95%CI) =
1.73(1.02–2.95), p = 0.044) or limited joints restricted in
movement (OR(95%CI) = 1.57(1.06–2.32), p = 0.026) com-
pared to patients with a low pain trajectory (Table 2). PGA
continues to be associated with increased pain (OR
(95%CI) = 1.44(1.03–2.02), p = 0.033).
Patients with variable pain were also more likely to have
limited joints (OR (95%CI) = 1.53(1.04–2.26), p = 0.033)
than patients with low pain (Table 2) and have a trend to-
wards having less active joints (OR (95%CI) = 0.73(0.50–
1.06), p = 0.096) and more swollen joints (OR (95%CI) =
1.59(0.99–2.57), p = 0.057). This trajectory was not associ-
ated with PGA (OR (95%CI) = 1.22(0.90–1.64), p = 0.20).
Analysis of the distribution of these three joint mea-
sures (active, swollen, limited) within patients of each
trajectory type revealed that the pattern of joint types
differed significantly between the low and variable/high
pain trajectories with fewer patients with only active
joints but more patients with swollen and limited joint
in patients with a variable/high pain trajectory (Fisher =
21.82, p = 0.029; Additional file 1: Figure S2).
This data suggests that patients with high levels of pain
have less active arthritis, but more symptoms associated
with arthritis activity at or before the onset of the study.
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Part 2: pain in a rodent model of joint inflammation
The data above shows that while that active arthritis is less
likely in patients with high pain, they are more likely to
have swollen and limited joints, indicating that prior arth-
ritic activity may contribute to their high pain trajectory.
To test whether there is a causal relationship between
current pain sensitivity and prior joint inflammation, in
the absence of other extraneous factors, we next turned to
an experimental model of monoarthritis in rodents.
Inflammatory pain behaviour in a rodent model also
follows three pain trajectories not associated with arthritic
activity
Adolescent rats (P21) with complete Freund’s adjuvant
(CFA) induced monoarthritis exhibited clear pain behav-
iour. This was measured by mechanical hypersensitivity
for 7 days post-CFA injection (F6,138 = 53.01, p < 0.001)
and reduced weight bearing on the inflamed limb for 21
days (F6,138 = 39.29, p < 0.001) with some variance. Based
on mechanical withdrawal thresholds 3–10 days post-
injection, animals could be separated into 3 clusters:
those with a low (28.0%), medium (36.0%) or high
(36.0%) sensitivity to pain. Animals in these three sensi-
tivity groups also exhibited mechanical hypersensitivity
after CFA injection for differing timescales (F2,126 = 6.65,
p < 0.001, Fig. 3a): 3 days for animals with low pain sen-
sitivity (0 vs. 3 days: p < 0.001), 7 days for animals with
medium sensitivity (0 vs. 3–7 days: p < 0.001), and 10
days for animals with high pain sensitivity (0 vs. 3–10
days: p < 0.001).
Weight bearing on the inflamed limb also differed be-
tween sensitivity groups (F2,21 = 2.39, p = 0.012, Fig. 3b)
with low pain sensitivity animals experiencing a smaller
reduction in weight bearing post-injection compared to
Fig. 2 Cluster analysis of Pain VAS from JIA patients revealed several distinct clusters (a). These could be separated into 3 functional groups based
on pain trajectory: patients with low levels of pain (n = 45, blue), patients with consistently high levels of pain (n = 22, orange) and patients with
varying levels of pain over the 50 week period (n = 30, green). Each of these functional groups consisted of a number of smaller clusters shown in
B, C, and D which show the clusters forming patients with high pain (b), variable pain (c) and low pain (d) respectively. Investigating the influence of
arthritic activity on pain across patients, pain at an individual visit was associated with physician global assessment (PGA, β = 0.53, p < 0.001, e) but not
the number of active joints (β = − 0.04, p = 0.67, f). Lines of best fit shown account for other factors included in the regression model
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animals with a medium (vs. low: p = 0.012) or high pain
sensitivity (vs. low: p = 0.044).
Females exhibited increased sensitivity with signifi-
cantly more female rats having medium or high pain
sensitivity compared to males (Chi-Square = 58.40, p <
0.001, Fig. 3c, Additional file 1: Table S3).
Arthritic activity did not account for pain sensitivity.
Joint diameter (an indicator of the degree of joint inflam-
mation) did not correlate with pain behaviour 3 days post-
injection (F1,9 = 0.37, p = 0.56) and did not significantly
differ between the three sensitivity types over 21 days
post-injection (F2,8 = 0.12, p = 0.89, Fig. 3d). This data is
consistent with the pattern seen in patients in Part 1.
Prior joint inflammation increases pain only in animals with
high pain sensitivity
To test whether pain trajectory is influenced by previous
arthritic activity, pain behaviour was assessed in animals
administered low dose joint CFA (or saline as a control)
twice: once at P8 or P21, and again at P40 (Fig. 4a). Overall,
pain behaviour in animals with two bouts of monoarthritis
(CFA +CFA) was comparable to animals experiencing
monoarthritis for the first time (Saline+CFA). Mechanical
withdrawal threshold was reduced for 14 days post-injec-
tion in both groups (F18,576 = 8.43, p < 0.001; Saline+CFA
vs. Saline+Saline controls: p < 0.001; CFA +CFA vs.
Saline+Saline: p < 0.010). Weight bearing on the inflamed
limb (F18,576 = 27.15, p < 0.001) was reduced for 21 days
post-injection in Saline+CFA animals (vs. Saline+Saline:
p < 0.001) and 24 days post-injection in CFA +CFA animals
(vs. Saline+Saline: p < 0.05).
However, when CFA + CFA animals were separated
into high or low pain sensitivity phenotypes based on
their baseline levels of sensitivity prior to the second
bout of CFA, significant differences emerged. The high
sensitivity group were defined by their significantly lower
baseline weight bearing compared to Saline+Saline and
Saline+CFA animals (F3.63 = 22.02, p < 0.001; vs. Saline+-
Saline/Saline+CFA: p < 0.001; Fig. 4b) which animals
with low sensitivity group did not have (vs. Saline+Sa-
line/Saline+CFA: p > 0.050). Sex distribution did not
differ the two groups (Chi Square = 0.40, p = 0.53, Add-
itional file 1: Table S4).
The effect of a second CFA injection upon pain behav-
iour, differed significantly between the low and high sen-
sitivity groups. Animals with high sensitivity experienced
significantly longer lasting pain, measured as a reduction
in weight bearing, after the second CFA injection
(F27,567 = 19.09, p < 0.001, Fig. 4c) compared to low sen-
sitivity or Saline+CFA animals, from 17 to 24 days post-
injection (vs. low sensitivity/Saline+CFA: p < 0.05). Re-
ductions in mechanical withdrawal threshold (F21,441 =
Table 2 Association between patient characteristics/JIA indicators and pain trajectories
Average (mean (SD), no. (%), median (IQR)) Association with … relative to low pain
Low pain Variable pain High pain Variable pain High pain
n = 45 n = 30 n = 22 OR (95%CI) P value OR (95%CI) P value
Patient characteristics
Age at JIA onset 9.51 (4.71) 9.96 (4.88) 9.40 (5.31) 1.00 (0.88–1.15) 0.98 1.08 (0.93–1.25) 0.34
Age at study onset 16.19 (1.18) 16.46 (1.16) 16.76 (1.31) 1.38 (0.86–2.21) 0.19 1.56 (0.87–2.79) 0.13
Female sex (ref: male) 24 (53.3%) 13 (43.3%) 18 (81.8%) 0.50 (0.14–1.82) 0.29 2.92 (0.53–16.15) 0.22
JIA subtype (ref: polyarticular course)
Enthesitis Related 15 (33.3%) 13 (43.3%) 4 (18.2%) 1.35 (0.32–5.60) 0.68 0.59 (0.09–3.72) 0.57
Oligoarticular 4 (8.9%) 1 (3.3%) 1 (4.5%) 0.69 (0.06–8.19) 0.77 0.52 (0.03–8.79) 0.65
Medications (ref: not in use for each type)
DMARDs 27 (60.0%) 22 (73,3%) 18 (81.8%) 1.35 (0.32–5.60) 0.40 3.72 (0.78–17.69) 0.098
Biologics 18 (40.0%) 12 (40.0%) 10 (45.5%) 1.01 (0.32–3.18) 0.98 1.90 (0.47–7.74) 0.37
Steroids 4 (8.9%) 7 (23.3%) 5 (22.7%) 1.11 (0.16–7.59) 0.91 0.68 (0.08–5.79) 0.73
JIA activity markers at study onset
PGA 1.40 (2.11) 3.11 (2.73) 3.47 (2.31) 1.22 (0.90–1.64) 0.20 1.44 (1.03–2.02) 0.033
No. of:
Active joints 0 (0–1) 1 (0–1) 0 (0–2) 0.73 (0.50–1.06) 0.096 0.62 (0.40–0.97) 0.035
Swollen joints 0 (0–0) 1 (0–2.25) 1 (0–3) 1.59 (0.99–2.57) 0.057 1.73 (1.02–2.95) 0.044
Limited joints 0 (0–1) 2 (0–3) 2 (0–5) 1.53 (1.04–2.26) 0.033 1.57 (1.06–2.32) 0.026
Data is described as mean (standard deviation (SD)) for continuous data, number (% of patients with trajectory type) for categorical data or median (interquartile
range (IQR)) for discrete data (joint count). Factors which are significantly associated (p < 0.05) with variable or high pain are indicated in bold. PGA = Physician
global assessment VAS. DMARDs = Disease-modifying antirheumatic drugs. OR (95%CI) = Odds Ratio (95% Confidence Interval)
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11.96, p < 0.001) and joint inflammation did not differ
between groups (F27,567 = 5.76, p < 0.001).
This data shows that rodents, like human patients,
vary in their sensitivity to joint inflammation. The data
also shows that prior inflammatory activity does lead to
enhanced monoarthritic pain, but only in those animals
that have a higher sensitivity at baseline.
Discussion
Here we have used a combination of JIA patient data and
rodent inflammatory pain behaviour to identify and exam-
ine factors which contribute to persistent pain in children
with JIA. The first part of the study identified 3 trajector-
ies of pain over 50 weeks in adolescents with JIA. Pain tra-
jectory was not dependent on current arthritic activity (as
measured by active joint count), nor did other discrete dis-
ease-related variables (JIA subtype or medications admin-
istered) differ between trajectories. However, a different
subjective measure of disease activity–the physicians’ as-
sessment (PGA)–did correlate with pain reported at an in-
dividual visit. Evaluating factors related to each pain
trajectory we found that, while active arthritis is less likely
in patients with high pain, these patients had more
swollen and limited joints suggesting that prior arthritic
activity may influence the progression of pain.
This was explored in the second part of the study using
an experimental animal model of joint inflammation to
examine the role of prior inflammation in the develop-
ment of persistent pain. Recurrent joint inflammation was
established through the administration of CFA at two
time-points. As predicted from the patient data, a prior
bout of inflammation exacerbated pain, measured by
weight bearing, but only in animals with higher baseline
levels of pain sensitivity.
Divergent pain trajectories have been shown previously
in JIA [8–10]. Studies describe a consistently low pain tra-
jectory in many patients (≥50%) and a persistently high
pain trajectory in 11.1% [8] or 17.9% [9] of patients, lower
than reported here (24.2%). These previous studies
focussed on pain in patients with new-onset JIA, whereas
this is the first longitudinal study in adolescent patients
with established JIA (average: 6.88 ± 5.21 years, range: 0.5–
17.45 years), mapping pain levels across a year. Increased
disease duration is the likely reason for the higher percent-
age of patients with high pain reported here and is consist-
ent with studies measuring JIA pain at later time-points
(up to 30 years), which describe persistent pain in 19% of
Fig. 3 Cluster analysis of mechanical withdrawal threshold in rats aged P21 following monoarthritis revealed three distinct clusters (a). These
could be related to differing pain trajectories with mechanical hypersensitivity (a reduction in mechanical withdrawal threshold) lasting different
lengths of time (p < 0.001): 3 days for animals with low sensitivity to inflammatory pain (n = 7, blue; p < 0.001), 7 days for animals with a medium
sensitivity to inflammatory pain (n = 9, green; p < 0.001), and 10 days for animals with a high sensitivity to inflammatory pain (n = 9, orange; p <
0.001). Weight bearing also differed between the sensitivity groups with animals with low sensitivity having a smaller reduction in weight bearing
post-CFA compared to animals with medium or high sensitivity (p = 0.012, b). Females were more likely to have medium or high sensitivity (p <
0.001, c). These differing sensitivities to inflammatory pain were despite no difference in joint inflammation between the three groups (p = 0.89,
d). * p < 0.05 between baseline mechanical threshold (0 day time-point) and indicated time-points for each sensitivity group as shown by the line
colour. + p < 0.05 between indicated groups
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patients [5, 21]. With the exception of the low and high
pain trajectories described above, [8, 9] studies typically
report pain which decreases over the first year from diag-
nosis before stabilising, [8–10, 14] a trajectory not preva-
lent here. Three patients in our variable pain trajectory
had new-onset JIA (<1 year since diagnosis) and match
this profile, but much of the group does not.
Psychosocial variables (ranging from depressive symp-
toms to health beliefs) were not included in this analysis
due to the retrospective nature of the data collection.
Despite this limitation, our data suggests that prior arth-
ritic activity can exacerbate pain in individuals with high
sensitivity to inflammatory pain. In patients, increased
limited joint count was associated with variable and high
Fig. 4 Pain behaviour was measured in animals receiving intraarticular injections of CFA or saline twice (at either P8/P21 followed by P40, a).
CFA + CFA animals could be separated into animals with high or low pain sensitivity based on weight bearing measurements taken at baseline–
prior to the second monoarthritis induction (subgroups indicated by dashed boxes). Animals with high pain sensitivity (n = 9, orange) have a
significant reduction in baseline weight bearing compared to Saline+CFA (n = 22, purple) or Saline+Saline animals (n = 24, black) (p < 0.001, b)
while those with a low pain sensitivity (n = 12, blue) did not. Following monoarthritis induction animals with high pain sensitivity experienced a
prolonged reduction in weight bearing compared to animals with low pain sensitivity and Saline+CFA animals (p < 0.001, c). + p < 0.05 between
indicated groups. * p < 0.05 between high sensitivity and low sensitivity/Saline+CFA at indicated time-points
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pain trajectories, despite a lack of correlation between
limited joints and pain reported at a single visit. Limited
joint count is not typically included in analyses of factors
influencing pain, indicating the novelty of this discovery.
However, association does not necessarily indicate cause
and it is hard to define the chronology of arthritic activ-
ity and pain. Indeed, pain within 6 months of JIA onset
has been associated with increased disease severity, not-
ably polyarticular disease and continued pain/disability
at 5 or 8 years after JIA onset [10, 22].
Severe JIA has been differentiated into those requiring
more medication but achieving control of arthritic activ-
ity and pain and those who, despite intensive treatments
and comparable arthritic activity, continue to report pain
and reduced quality of life [10]. This suggests that there
are individual sensitivities to pain beyond arthritis itself,
a feature observed in other chronic pain conditions [23].
Research in this area has focussed upon differences in
individual neural pain pathways due to genetic and epi-
genetic processes, alterations in brain networks con-
cerned with reward, motivation/learning and descending
modulatory control and ‘priming’ of the pain system by
previous pain and trauma [24].
With variations present in the pain trajectories in JIA pa-
tients, cross-species studies can facilitate characterisation of
the relationship between disease activity and pain and dis-
sect out underlying mechanisms. Our results from rodents
suggest that–even within a colony of Sprague Dawley rats
from a single institution–there are differences in innate
sensitivity to inflammatory pain leading to low or high pain
trajectories in arthritis. Here we show that the relationship
between high pain and prior arthritic activity is dependent
on this sensitivity. Individual pain sensitivities in rodents
have been described elsewhere, focussing on genetic differ-
ences between rodent strains [25–27] or between sexes
[28]. Individual differences in the response to acute noxious
stimuli in rats of the same strain have been reported previ-
ously, [29, 30] but differences in the pain behaviour trajec-
tories following joint inflammation has not.
We have previously proposed that preceding painful
events may exacerbate pain in JIA, [31] and here we pro-
vide the first evidence supporting this proposal. Pain
priming in early life has been established in rodent
models of surgical pain, cutaneous and visceral inflam-
mation (reviewed in [32]), but this is the first demonstra-
tion that low doses of CFA–inducing transient joint
inflammation in juvenile animals exacerbates pain be-
haviour in adult rats. This model can be used to further
dissect the mechanisms underlying persistent JIA pain
and its relationship with previous inflammatory pain ex-
posure, particularly the role of neuroimmune interac-
tions in central pain circuits, which may establish a
prolonged state of central sensitization not related to
current inflammation [18, 33].
Conclusions
This work shows that both patients with JIA and rodents
with experimental joint inflammation have individual
sensitivities to arthritic inflammatory pain which is not
related to current joint inflammatory status. A signifi-
cant number of both JIA patients and rodent models
have pain that is persistently higher or more prolonged
than other individuals of the same age, sex and arthritic
activity. The results support the hypothesis that prior,
rather than current, arthritic activity may be an explana-
tory factor for those individuals with a high sensitivity to
inflammatory pain.
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